Straits Times Index
3,179.78 -7.88 (-0.25%) Nikkei
36,987.87 -1,091.83 (-2.87%) Hang Seng
16,385.87 0.00 (0.00%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
61,786.90 +282.30 (+0.46%) CMC Crypto 200
1,286.26 +400.72 (+44.00%)
BrainsWay Ltd. (BWAY)
After hours:
| Previous close | 5.0500 |
| Open | 5.1200 |
| Bid | 4.7500 x 100 |
| Ask | 4.9200 x 100 |
| Day's range | 4.6100 - 5.1800 |
| 52-week range | 1.3800 - 7.6150 |
| Volume | |
| Avg. volume | 112,320 |
| Market cap | 80.953M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.85 |
GlobeNewswireBrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS™ treatment in Israel. BrainsWay has steadily increased its presence in the country with 11 recent system installatio
- GlobeNewswire
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor SymptomsJERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic approach for Park
- GlobeNewswire
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of late-life depression. The data wer
